The state of Virginia currently has 80 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. These trials are conducted in various cities, including Richmond, Charlottesville, Norfolk and Fairfax.
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Virginia Cancer Care Specialist, PC, Fairfax, Virginia
Conditions: Resectable Non-small Cell Lung Cancer
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Recruiting
BH-30643-01 is a Phase 1/2, first-in-human, open label, dose escalation and expansion study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Research Site, Fairfax, Virginia +1 locations
Conditions: Metastatic Non-small Cell Lung Cancer
A Study to Learn About Study Medicine ALTA3263 in Adults with Advanced Solid Tumors with KRAS Mutations
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (non-small Cell Lung Cancer), CRC (colorectal Cancer), Advanced Solid Tumors
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Recruiting
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced Non-Small Cell Lung Cancer
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Recruiting
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/06/2025
Locations: Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia
Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Recruiting
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Research Site, Charlottesville, Virginia +3 locations
Conditions: Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Recruiting
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to te... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Virginia Cancer Specialists, PC, Fairfax, Virginia
Conditions: Neoplasm Metastasis, Non-Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recruiting
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Metastatic Non-small Cell Lung Cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Local Institution - 007-814-A, Alexandria, Virginia +5 locations
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: USOR Virginia Cancer Specialists, Fairfax, Virginia +1 locations
Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia
Conditions: Non-Small Cell Lung Cancer